NorthCrest Asset Manangement LLC Acquires New Shares in Insmed, Inc. $INSM

Posted by Geri Gentry on Oct 17th, 2026

NorthCrest Asset Manangement LLC acquired a new stake in shares of Insmed, Inc. (NASDAQ:INSM – Free Report) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 5,710 shares of the biopharmaceutical company’s stock, valued at approximately $652,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Private Advisor Group LLC boosted its holdings in Insmed by 1.8% in the first quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock worth $777,000 after purchasing an additional 82 shares during the last quarter. Glenmede Trust Co. NA grew its position in Insmed by 5.4% in the 1st quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 98 shares during the period. Values First Advisors Inc. grew its position in Insmed by 7.1% in the 1st quarter. Values First Advisors Inc. now owns 2,203 shares of the biopharmaceutical company’s stock worth $360,000 after purchasing an additional 146 shares during the period. Reflection Asset Management purchased a new stake in Insmed during the 4th quarter valued at $30,000. Finally, American Trust raised its stake in Insmed by 12.9% during the 1st quarter. American Trust now owns 1,710 shares of the biopharmaceutical company’s stock valued at $280,000 after buying an additional 196 shares during the last quarter.

Insmed Stock Performance

INSM traded down $2.94 during midday trading on Friday, reaching $96.27. The company had a trading volume of 2,396,052 shares, compared to its average volume of 2,873,486. The business has a 50-day moving average of $118.77 and a two-hundred day moving average of $118.27. The company has a quick ratio of 3.40, a current ratio of 3.72 and a debt-to-equity ratio of 0.74. Insmed, Inc. has a 1 year low of $90.39 and a 1 year high of $212.75. The company has a market cap of $21.02 billion, a P/E ratio of -23.42 and a beta of 0.83.

Insmed (NASDAQ:INSM – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.61. Insmed had a negative return on equity of 123.94% and a negative net margin of 76.94%. The firm had revenue of $425.49 million for the quarter, compared to analysts’ expectations of $395.50 million. During the same period in the previous year, the firm earned ($1.70) EPS. The business’s quarterly revenue was up 296.1% on a year-over-year basis. As a group, equities research analysts predict that Insmed, Inc. will post -1.72 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. UBS Group reissued a “buy” rating on shares of Insmed in a report on Thursday, October 8th. BMO Capital Markets restated an “outperform” rating on shares of Insmed in a research note on Tuesday, October 6th. JPMorgan Chase & Co. cut their price objective on Insmed from $179.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, August 10th. Roth Capital reiterated a “buy” rating and set a $198.00 price objective (down from $212.00) on shares of Insmed in a research report on Tuesday, September 15th. Finally, Bank of America reiterated a “buy” rating and set a $207.00 price objective on shares of Insmed in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Insmed currently has a consensus rating of “Moderate Buy” and an average target price of $200.30.

Read Our Latest Research Report on Insmed

Insider Activity at Insmed

In related news, Director David Brennan sold 25,000 shares of the stock in a transaction that occurred on Wednesday, September 9th. The shares were sold at an average price of $124.00, for a total value of $3,100,000.00. Following the completion of the sale, the director directly owned 39,238 shares of the company’s stock, valued at approximately $4,865,512. This represents a 38.92% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $133.27, for a total transaction of $31,964,809.50. Following the sale, the chief operating officer owned 98,744 shares in the company, valued at approximately $13,159,612.88. The trade was a 70.84% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 2.10% of the company’s stock.

Insmed Company Profile

(Free Report)

Insmed Incorporated is a global biopharmaceutical company focused on developing and commercializing therapies for patients with serious and rare diseases. The company’s research and development activities center on pulmonary and inflammatory conditions, with an emphasis on diseases that have limited treatment options.

Insmed’s principal commercial product is ARIKAYCE liposomal, an inhaled formulation of amikacin used with a combination antibacterial regimen to treat refractory Mycobacterium avium complex lung disease in certain adult patients.